Novartis AG PE Ratio 2006-2018 | NVS

Current and historical p/e ratio for Novartis AG (NVS) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of October 17, 2018 is 17.04.
Novartis AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-10-17 85.28 14.48
2018-06-30 75.54 $5.89 12.83
2018-03-31 80.85 $3.41 23.71
2017-12-31 81.04 $3.25 24.94
2017-09-30 82.87 $2.81 29.49
2017-06-30 80.57 $2.74 29.40
2017-03-31 71.69 $2.66 26.95
2016-12-31 67.87 $2.80 24.24
2016-09-30 73.57 $2.84 25.91
2016-06-30 76.88 $2.80 27.46
2016-03-31 67.50 $2.80 24.11
2015-12-31 77.20 $7.28 10.60
2015-09-30 82.47 $7.45 11.07
2015-06-30 88.23 $7.99 11.04
2015-03-31 88.48 $8.27 10.70
2014-12-31 80.86 $4.14 19.53
2014-09-30 82.14 $4.35 18.88
2014-06-30 79.00 $3.94 20.05
2014-03-31 74.19 $3.94 18.83
2013-12-31 67.88 $3.72 18.25
2013-09-30 64.78 $3.73 17.37
2013-06-30 59.71 $3.84 15.55
2013-03-31 60.16 $3.92 15.35
2012-12-31 51.50 $3.90 13.21
2012-09-30 49.84 $3.55 14.04
2012-06-30 45.48 $3.55 12.81
2012-03-31 45.08 $3.55 12.70
2011-12-31 44.52 $3.80 11.72
2011-09-30 43.43 $4.26 10.20
2011-06-30 47.59 $4.24 11.22
2011-03-31 42.33 $4.19 10.10
2010-12-31 44.02 $4.28 10.29
2010-09-30 43.07 $4.35 9.90
2010-06-30 36.08 $4.28 8.43
2010-03-31 40.40 $4.11 9.83
2009-12-31 39.21 $3.69 10.63
2009-09-30 36.29 $3.34 10.87
2009-06-30 29.38 $3.34 8.80
2009-03-31 27.25 $3.44 7.92
2008-12-31 34.33 $3.59 9.56
2008-09-30 36.45 $3.34 10.91
2008-06-30 37.97 $5.39 7.04
2008-03-31 35.34 $5.26 6.72
2007-12-31 36.40 $5.16 7.05
2007-09-30 36.83 $5.45 6.76
2007-06-30 37.58 $3.28 11.46
2007-03-31 36.61 $3.15 11.62
2006-12-31 37.78 $3.06 12.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $198.652B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.377B 17.18
Pfizer (PFE) United States $261.509B 15.31
Merck (MRK) United States $192.023B 16.96
AbbVie (ABBV) United States $139.177B 13.60
Eli Lilly (LLY) United States $119.245B 22.07
Sanofi (SNY) France $111.234B 14.08
Novo Nordisk (NVO) Denmark $106.025B 16.95
AstraZeneca (AZN) United Kingdom $98.986B 10.89
GlaxoSmithKline (GSK) United Kingdom $98.701B 13.18
Bristol-Myers Squibb (BMY) United States $94.525B 17.11